Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

Assay for routine screening of CFTR gene, 7/17

July 2017—Swift Biosciences has commercially released its Accel-Amplicon CFTR Panel, which aims to provide research laboratories with a more comprehensive, next-generation sequencing–based approach to interrogate the coding region and select introns within the cystic fibrosis transmembrane conductance regulator gene for disease-relevant mutations and variants. The panel is designed to offer a higher resolution view into the CFTR gene and produces ready-to-sequence libraries in two hours.

Semi-motorized fluorescence microscope, 7/17

July 2017—Olympus’ new BX53 microscope features an LED illuminator equivalent to a 100-watt halogen lamp that delivers outstanding brightness and true-to-life images, according to the company. The LED enables researchers to clearly see purple, cyan, and pink dyes while its consistent color temperature aims to help speed up the observation workflow, since users don’t have to take time adjusting a color filter. The coded nosepiece works with the light intensity manager to automatically adjust the brightness level based on the objective being used.

Heparin calibration verification/linearity test kit, 6/17

June 2017—LGC Maine Standards’ Validate Heparin calibration verification/linearity test kit received FDA 510(k) clearance for use on Instrumentation Laboratory’s ACL TOP 500 hemostasis test systems. The Validate Heparin kit evaluates heparin anti-Xa activity in a human plasma matrix, is prepared using CLSI’s EP06-A recommended equal delta method for linearity testing, and is liquid, ready to use.

Cobas HPV assay, 6/17

June 2017—Roche announced the CE-IVD launch of Cobas HPV for use on the Cobas 6800/8800 Systems for cervical cancer screening. This HPV DNA assay gives laboratories the ability to run HPV DNA testing simultaneously with other previously released Cobas assays, including chlamydia and gonorrhea (CT/NG), HIV-1, HCV, HBV, CMV, and three next-generation assays for donor screening: the Cobas MPX, Cobas WNV, and Cobas HEV.

RNA-based biomarker panel for cancer, 6/17

June 2017—Cofactor Genomics launched its Pinnacle assay, which looks at gene fusions and gene expression in patient tumor samples to provide physicians with potential treatment targets for cancer patients.

CE mark for Singulex IVD platform, 6/17

June 2017—Singulex announced it received the CE mark for the Sgx Clarity system, a fully automated in vitro diagnostics platform powered by single-molecule counting technology. Up to 1,000 times more sensitive than existing technologies, single- molecule counting technology measures biomarkers at the lowest levels, revealing the presence, or absence, of disease so clinicians can provide the right treatment at the right time.

IHC imaging and analysis system, 6/17

June 2017—Applied Spectral Imaging introduced its HiPath imaging and analysis system, which provides computer-assisted PD-L1 interpretation for research use.

CLSI phlebotomy documents, 6/17

June 2017—The Clinical and Laboratory Standards Institute has published two new phlebotomy documents, “Collection of Diagnostic Venous Blood Specimens (GP41-Ed7)” and “Essential Elements of a Phlebotomy Training Program (GP48-Ed1).”

Circulating cell-free DNA isolation kit, 6/17

June 2017—MagBio Genomics launched its cfKapture 21 kit, a circulating cell-free DNA isolation kit that includes a proprietary reagent designed to prevent post-separation degradation of plasma and ccfDNA fragments for up to 21 days at room temperature. This feature allows laboratories to safely transport and process samples in a longer time frame without the need for extensive cold chain.

MARKETPLACE

TRENDING